JMP Securities Reiterates Market Outperform on Ambrx Biopharma, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a 'Market Outperform' rating on Ambrx Biopharma (NASDAQ:AMAM) and maintained a price target of $15.
November 29, 2023 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Reni Benjamin has reiterated a 'Market Outperform' rating on Ambrx Biopharma and maintained a price target of $15.
The reiteration of a 'Market Outperform' rating and the maintenance of a $15 price target by a reputable analyst like Reni Benjamin could instill confidence in investors and positively influence the stock price of Ambrx Biopharma in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100